HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q1 2019 FINANCIAL RESULTS
* Q1 REVENUE OF $13.2 MILLION, ADJUSTED EBITDA OF $8.3 MILLION AND CASH FROM OPERATIONS OF $8.3 MILLION
* Q1 LOSS PER SHARE $0.14
* AS AT MARCH 31, 2019, COMPANY HAD CASH AND CASH EQUIVALENTS OF $12.8 MILLION, UP FROM $10.9 MILLION AT DECEMBER 31, 2018.